Blueprint Medicines Corporation

Blueprint Medicines Corporation

Blueprint Medicines was established as a publicly traded biotech before being acquired by Sanofi; the firm's current identity is as a Sanofi company headquartered in Cambridge, MA. It focuses on discovering and commercializing therapies targeting root causes of allergic/inflammatory diseases and cancer, with approved drugs AYVAKIT (avapritinib) for indolent and advanced systemic mastocytosis and certain gastrointestinal stromal tumors. The company's R&D strategy spans multiple modalities, including kinase inhibitors, targeted protein degradation, and AI/ML-enhanced discovery. Its pipeline includes elenestinib for mast cell disorders and BLU-808 for chronic urticaria and other mast cell-mediated diseases. Blueprint Medicines has developed a global commercial reach with approved drugs in the U.S. and Europe, and operates a named patient program outside those regions. As of February 2026, the firm reported four-year PIONEER data showing sustained benefit and long-term safety of AYVAKIT in indolent systemic mastocytosis (per the company, February 2026). The team numbers over 1,000 professionals globally, with additional office in Zug, Switzerland. The company runs patient support programs like YourBlueprint for U.S. patients. Blueprint Medicines’ structural differentiator is its acquisition by Sanofi, integrating a precision medicine pipeline into a large pharma infrastructure while maintaining an independent operating identity. The firm’s focus on rare mast cell disorders and targeted oncology gives it a distinct niche within Sanofi's broader portfolio.